ATXS Astria Therapeutics, Inc. Stock Quote

ATXS [NASD]

Index	-	P/E	-	EPS (ttm)	-54.23	Insider Own	2.00%	Shs Outstand	12.83M	Perf Week	5.89%
Market Cap	60.21M	Forward P/E	-	EPS next Y	-2.61	Insider Trans	0.04%	Shs Float	12.74M	Perf Month	-8.04%
Income	-218.80M	PEG	-	EPS next Q	-0.66	Inst Own	64.20%	Short Float	0.91%	Perf Quarter	-22.97%
Sales	-	P/S	-	EPS this Y	13.40%	Inst Trans	9.36%	Short Ratio	2.44	Perf Half Y	-50.39%
Book/sh	2.65	P/B	1.90	EPS next Y	93.20%	ROA	-185.30%	Target Price	22.80	Perf Year	-67.63%
Cash/sh	11.01	P/C	0.46	EPS next 5Y	-	ROE	-	52W Range	4.30 - 47.82	Perf YTD	-6.68%
Dividend	-	P/FCF	-	EPS past 5Y	37.50%	ROI	-	52W High	-89.27%	Beta	1.44
Dividend %	-	Quick Ratio	28.60	Sales past 5Y	-	Gross Margin	-	52W Low	19.30%	ATR	0.45
Employees	20	Current Ratio	28.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.98	Volatility	8.49% 9.15%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	81.70%	Profit Margin	-	Rel Volume	0.19	Prev Close	5.03
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 10 BMO	Payout	-	Avg Volume	47.37K	Price	5.13
Recom	1.20	SMA20	-2.30%	SMA50	-12.57%	SMA200	-44.92%	Volume	498	Change	1.99%

Nov-10-21 08:00AM	Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update Business Wire
Nov-09-21 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference Business Wire
Nov-05-21 08:00AM	Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema Business Wire
Oct-27-21 08:00AM	Astria Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Developments on Wednesday, November 10 Business Wire
Oct-21-21 08:00AM	Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting Business Wire
Oct-18-21 08:00AM	Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit Business Wire -7.54%
Oct-12-21 08:00AM	Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit Business Wire
Oct-03-21 09:52PM	3 Stocks That Could Double From Current Levels; Oppenheimer Says Buy TipRanks
Sep-10-21 08:00AM	Astria Therapeutics to Present at Upcoming Investor Conferences Business Wire

Astria Therapeutics, Inc., a biopharmaceutical company, engages in developing therapies for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-021, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development stage for the treatment of hereditary angioedema, a rare genetic disorder causing swelling in the face, limbs, abdomen, and airway. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Komjathy Andrew	Chief Commercial Officer	Nov 19	Buy	6.70	100	670	100	Nov 23 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience